Statin therapy may exacerbate underlying neuromuscular disorders. ‼️REMEMBER☝️The only ABSOLUTE contraindication to statins are pts who are HMGCR+ #ACR22 @RheumNow #acrreview https://t.co/A3XGHlrm0X

How long do we hold meds for live-attenuated #Vaccines? ACR 2022 vax guidelines: 💉Pre-vax: 💊csDMARDs - hold time 4 wks 💊bDMARDs -hold time of one dosing interval 💉Post-vax: hold DMARDs for 4 wks #ACR22 @rheumnow @rheumarhyme @doktora_ging https://t.co/MGc422EtIC

Patel @NaomiRheumMD et al. HbA1c in GiACTA. Tocilizumab assoc HbA1c reduction independent of steroids. Daily steroid dose assoc HbA1c @rheumnow #ACR22 Abstr#0461 https://t.co/9Nbewrpww8 https://t.co/NyeTyWICF6

• The Effects of Daily Prednisone and Tocilizumab on Hemoglobin A1c During the Tr…

🪞MIRROR RCT🪞 💊MTX ⬆️ response of Pegloticase in resistant gout pts (60% vs PBO 30.8%) 🦶Tophus resolution wk 52 >24 (cont. benefit💪🏻) 🧪⬇️ drug Ab with MTX ✅ No new IRs Abst#0001 #ACR22 @RheumNow #plenary https://t.co/8lPKQ0VGqC

Ab0349 #ACR22 BEL vs AZA ifn risks in non-renal SLE BEL: lower risk of severe ifn (HR 0.81) and hospitalization for ifn (HR 0.73) through 5 yrs Challenge to interpret data as 56% of patients were on glucocorticoids and other anti-rheumatic meds @RheumNow https://t.co/a0tNFn5Wqr

MIRROR results showed 12-month safety/efficacy support MTX co-therapy w/ pegloticase. No IRs after 6mo of tx and increased resolution of tophi at wk 52. I use MTX in my gout pts on Pegloticase. Are you #rheumtwitter? Abs 0001 #ACR22 @RheumNow https://t.co/FLwOmAYrS4

• 12-month Findings of the Randomized, Double-Blind, Placebo-Controlled, Multicen…

Study of IV tocilizumab for GCA that led to FDA approval of intravenous TCZ this year (2/2022) -one of Dr. C Langford's pick for #YearinReview @rheumnow #ACR22 https://t.co/luxDDluddM

• Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia R…

Is it the medication or behaviour that increases mortality? #SLICC grp showed in #SLE severe non-adherence to #HCQ in Yr 1 of #lupus = 3 poor outcomes -more 1 flares, 2 damage, 3 5yr-death. Surrogate of other poor health behaviours and/or HCQ? abst#0343 #ACR22 #ACRBest @RheumNow https://t.co/tTRdyti0sf

Ab0343. #ACR22 Severe non-adherence of HCQ associated with FLARES, DAMAGE and DEATH 7.3% had "severe non-adherence" by HCQ levels Hazard ratio of flare 3.3, damage 4.26, and death 5.4 Not surprising, but very useful for pt discussion Checking HCQ levels are helpful! @Rheumnow https://t.co/S7P9oTPRGJ

Ab0344 #ACR22 CKD2+ a/w incr HCQ levels by 149 ng/mL vs CKD1 400 mg/d dose: incr HCQ levels by 448 ng/mL vs 200 Incr body wt by 15 kg -> decr HCQ levels by 82 ng/mL Social determinants didn't effect data >750ng/mL and >1000 predicted of 75% decr flare risk @Rheumnow #ACRBest https://t.co/p21rqnO4ym